Profile of pegvisomant in the management of acromegaly: an evidence based review of its place in therapy

References

• Melmed S. Medical progress: Acromegaly. N Engl J Med. 2006;355(24):2558–2573.
   PubMed Web of Science ®Google Scholar
• Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–3951.
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2011;32(2):247–271.
   PubMed Web of Science ®Google Scholar
• Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157–198.
   PubMed Web of Science ®Google Scholar
• Duran-Prado M, Saveanu A, Luque RM, et al. A potential inhibitory role for the new truncated variant of somatostatin receptor (5), sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J Clin Endocrinol Metab. 2010;95(5):2497–2502.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Kasuki L, Korbonits M. Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab. 2013;24(5):238–246.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA):a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–884.
   PubMed Web of Science ®Google Scholar
• Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96(5):1327–1335.
   PubMed Web of Science ®Google Scholar
• Higham CE, Atkinson AB, Aylwin S, et al. Effective Combination Treatment with Cabergoline and Low-Dose Pegvisomant in Active Acromegaly: A Prospective Clinical Trial. J Clin Endocrinol Metab. 2012;97(4):1187–1193.
   PubMed Web of Science ®Google Scholar
• Bernabeu I, Alvarez-Escola C, Paniagua AE, et al. Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary. 2013;16(1):101–108.
   PubMed Web of Science ®Google Scholar
• Gent J, van Kerkhof P, Roza M, Bu G, Strous GJ. Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis. Proc Natl Acad Sci U S A. 2002;99(15):9858–9863.
   Web of Science ®Google Scholar
• Brown RJ, Adams JJ, Pelekanos RA, et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol. 2005;12(9):814–821.
   PubMed Web of Science ®Google Scholar
• Carter-Su C, Smit LS. Signaling via JAK tyrosine kinases: growth hormone receptor as a model system. Recent Prog Horm Res. 1998;53:61–82.
   PubMedGoogle Scholar
• Berg CA, Pokrajac A, Bidlingmaier M, Strasburger CJ, Shalet SM, Trainer PJ. Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF-I in adults with severe GH deficiency (GHD). Clin Endocrinol (Oxf). 2009;70(3):439–445.
   Web of Science ®Google Scholar
• Ross RJ, Esposito N, Shen XY, et al. A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein. Mol Endocrinol. 1997;11(3):265–273.
   PubMedGoogle Scholar
• Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev. 2002;23(5):623–646.
   PubMed Web of Science ®Google Scholar
• Ross RJ, Leung KC, Maamra M, et al. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab. 2001;86(4):1716–1723.
   Web of Science ®Google Scholar
• Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171–1177.
   PubMed Web of Science ®Google Scholar
• Madsen M, Fisker S, Feldt-Rasmussen U, et al. Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly. Clin Endocrinol (Oxf). 2014;80(1):92–100.
   Web of Science ®Google Scholar
• Paisley AN, Hayden K, Ellis A, Anderson J, Wieringa G, Trainer PJ. Pegvisomant interference in GH assays results in underestimation of GH levels. Eur J Endocrinol. 2007;156(3):315–319.
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295):1754–1759.
   PubMed Web of Science ®Google Scholar
• Herman-Bonert VS, Zib K, Scarlett JA, Melmed S. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab. 2000;85(8):2958–2961.
   PubMed Web of Science ®Google Scholar
• Drake WM, Parkinson C, Akker SA, Monson JP, Besser GM, Trainer PJ. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. Eur J Endocrinol. 2001;145(4):451–456.
   PubMed Web of Science ®Google Scholar
• Buchfelder M, Schlaffer S, Droste M, et al. The German ACROSTUDY: past and present. Eur J Endocrinol. 2009;161 Suppl 1:S3–S10.
   Google Scholar
• Trainer PJ. ACROSTUDY: the first 5 years. Eur J Endocrinol. 2009;161 Suppl 1:S19–S24.
   Google Scholar
• van der Lely AJ, Biller BM, Brue T, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab. 2012;97(5):1589–1597.
   PubMed Web of Science ®Google Scholar
• Brue T, Castinetti F, Lundgren F, Koltowska-Haggstrom M, Petrossians P; ACROSTUDY investigators. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY. Eur J Endocrinol. 2009;161 Suppl 1:S11–S17.
   Google Scholar
• Brue T. ACROSTUDY: Status update on 469 patients. Horm Res. 2009;71 Suppl 1:34–38.
   Google Scholar
• Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ. Long-Term Treatment with Pegvisomant as Monotherapy in Patients with Acromegaly: Experience from Acrostudy. Endocr Pract. 2014;4:1–32.
   Google Scholar
• Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol. 2007;156(1):75–82.
   PubMed Web of Science ®Google Scholar
• Marazuela M, Lucas T, Alvarez-Escola C, et al. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur J Endocrinol. 2009;160(4):535–542.
   PubMed Web of Science ®Google Scholar
• Higham CE, Chung TT, Lawrance J, Drake WM, Trainer PJ. Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol (Oxf). 2009;71(1):86–91.
   PubMed Web of Science ®Google Scholar
• Sesmilo G, Resmini E, Bernabeu I, et al. Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study. Clin Endocrinol (Oxf). 2014;81(6):883–890.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, Franck SE, de Rooij FW, et al. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2014;99(10):3644–3652.
   PubMed Web of Science ®Google Scholar
• Pereira AM, Biermasz NR, Roelfsema F, Romijn JA. Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance. Treat Endocrinol. 2005;4(1):43–53.
   Google Scholar
• Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab. 2009;94(5):1500–1508.
   PubMed Web of Science ®Google Scholar
• Urbani C, Sardella C, Calevro A, et al. Effects of medical therapies for acromegaly on glucose metabolism. Eur J Endocrinol. 2013;169(1):99–108.
   Web of Science ®Google Scholar
• Rose DR, Clemmons DR. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res. 2002;12(6):418–424.
   PubMed Web of Science ®Google Scholar
• Drake WM, Rowles SV, Roberts ME, et al. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol. 2003;149(6):521–527.
   PubMed Web of Science ®Google Scholar
• Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005;90(10):5684–5691.
   PubMed Web of Science ®Google Scholar
• Jorgensen JO, Moller L, Krag M, Billestrup N, Christiansen JS. Effects of growth hormone on glucose and fat metabolism in human subjects. Endocrinol Metab Clin North Am. 2007;36(1):75–87.
   Web of Science ®Google Scholar
• Lindberg-Larsen R, Moller N, Schmitz O, et al. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab. 2007;92(5):1724–1728.
   PubMed Web of Science ®Google Scholar
• Droste M, Domberg J, Buchfelder M, et al. Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels. Eur J Endocrinol. 2014;171(1):59–68.
   Web of Science ®Google Scholar
• Berg C, Petersenn S, Lahner H, et al. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab. 2010;95(8):3648–3656.
   Web of Science ®Google Scholar
• Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM, Trainer PJ. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol (Oxf). 2002;56(3):303–311.
   Web of Science ®Google Scholar
• Sesmilo G, Fairfield WP, Katznelson L, et al. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab. 2002;87(4):1692–1699.
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Gomez R, Heissler JF, et al. Pregnancy in acromegaly patients treated with pegvisomant. Endocrine. Epub December 27, 2014.
   Google Scholar
• Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet. 2005;365(9471):1644–1646.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol. 2009;160(4):529–533.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, van Aken MO, de Herder WW, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab. 2008;93(10):3853–3859.
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Ezzat S, D’Souza GA, Layton G, Strasburger CJ. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf). 2009;71(4):549–557.
   PubMed Web of Science ®Google Scholar
• Jorgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab. 2005;90(10):5627–5631.
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Bernabeu I, Cap J, et al. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol. 2011;164(3):325–333.
   PubMed Web of Science ®Google Scholar
• Fisker S. Physiology and pathophysiology of growth hormone-binding protein: methodological and clinical aspects. Growth Horm IGF Res. 2006;16(1):1–28.
   Web of Science ®Google Scholar
• Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev. 2004;25(5):693–721.
   PubMed Web of Science ®Google Scholar
• Parkinson C, Burman P, Messig M, Trainer PJ. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab. 2007;92(1):190–195.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [homepage on the Internet]. Pegvisomant FDA Approval Package. Clinical Pharmacology and Biopharmaceutics review and Medical review; 2003. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021106_somavert.cfm. Accessed January 17, 2015.
   Google Scholar
• Leung KC, Doyle N, Ballesteros M, Waters MJ, Ho KK. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J Clin Endocrinol Metab. 2000;85(12):4712–4720.
   Web of Science ®Google Scholar
• Wurzburger MI, Prelevic GM, Sonksen PH, Wheeler M, Balint-Peric L. Effect of recombinant human growth hormone treatment on insulin-like growth factor (IGF-I) levels in insulin-dependent diabetic patients. Acta Diabetol. 1995;32(2):131–134.
   Web of Science ®Google Scholar
• Wurzburger MI, Prelevic GM, Sonksen PH, Balint-Peric LA, Wheeler M. The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes. J Clin Endocrinol Metab. 1993;77(1):267–272.
   Web of Science ®Google Scholar
• Kratzsch J, Keliner K, Zilkens T, Schmidt-Gayk H, Selisko T, Scholz GH. Growth hormone-binding protein related immunoreactivity is regulated by the degree of insulinopenia in diabetes mellitus. Clin Endocrinol (Oxf). 1996;44(6):673–678.
   Web of Science ®Google Scholar
• Mercado M, Gonzalez B, Sandoval C, et al. Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly. J Clin Endocrinol Metab. 2008;93(9):3411–3415.
   Web of Science ®Google Scholar
• Bianchi A, Mazziotti G, Tilaro L, et al. Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly. Pituitary. 2009;12(3):196–199.
   PubMed Web of Science ®Google Scholar
• Bernabeu I, Alvarez-Escola C, Quinteiro C, et al. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. J Clin Endocrinol Metab. 2010;95(1):222–229.
   Web of Science ®Google Scholar
• Filopanti M, Olgiati L, Mantovani G, et al. Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. J Clin Endocrinol Metab. 2012;97(2):E165–E172.
   PubMed Web of Science ®Google Scholar
• Akin F, Turgut S, Cirak B, Kursunluoglu R. IGF(CA)19 and IGFBP-3-202A/C gene polymorphism in patients with acromegaly. Growth Horm IGF Res. 2010;20(6):399–403.
   Web of Science ®Google Scholar
• Ramos-Levi AM, Marazuela M, Paniagua A, et al. Analysis of Igf(Ca)19 and Igfpb3 202a/C Gene Polymorphisms in Patients with Acromegaly: Association with Clinical Presentation and Response to Treatments. Eur J Endocrinol. 2015;172(2):115–122.
   Web of Science ®Google Scholar
• Buchfelder M, Weigel D, Droste M, et al. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol. 2009;161(1):27–35.
   PubMed Web of Science ®Google Scholar
• Marazuela M, Paniagua AE, Gahete MD, et al. Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. J Clin Endocrinol Metab. 2011;96(2):E251–E259.
   Web of Science ®Google Scholar
• Besser GM, Burman P, Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol. 2005;153(2):187–193.
   Web of Science ®Google Scholar
• Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab. 2010;21(10):610–618.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab. 2007;92(12):4598–4601.
   PubMed Web of Science ®Google Scholar
• Filopanti M, Barbieri AM, Mantovani G, et al. Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients. Eur J Endocrinol. 2013;170(2):247–254.
   Web of Science ®Google Scholar
• Biering H, Saller B, Bauditz J, et al. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol. 2006;154(2):213–220.
   Web of Science ®Google Scholar
• Feenstra J, van Aken MO, de Herder WW, Feelders RA, van der Lely AJ. Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. Eur J Endocrinol. 2006;154(6):805–806.
   Web of Science ®Google Scholar
• Bernabeu I, Cameselle-Teijeiro J, Casanueva F, Marazuela M. Pegvisomant-induced cholestatic hepatitis with jaundice in a patient with Gilbert’s syndrome. Eur J Endocrinol. 2009;160(5):869–872.
   Web of Science ®Google Scholar
• Bernabeu I, Marazuela M, Lucas T, et al. Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert’s syndrome. J Clin Endocrinol Metab. 2010;95(5):2147–2154.
   Web of Science ®Google Scholar
• Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed S. Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab. 2008;93(9):3515–3518.
   Web of Science ®Google Scholar
• Marazuela M, Dauden E, Ocon E, Moure D, Nattero L. Pegvisomant-induced lipohypertrophy: report of a case with histopathology. Ann Intern Med. 2007;147(10):741–743.
   Web of Science ®Google Scholar
• Paisley AN, Trainer PJ. The challenges of reliance on insulin-like growth factor I in monitoring disease activity in patients with acromegaly. Horm Res. 2004;62 Suppl 1:83–88.
   Google Scholar
• Plockinger U, Reuter T. Pegvisomant increases intra-abdominal fat in patients with acromegaly: a pilot study. Eur J Endocrinol. 2008;158(4):467–471.
   Web of Science ®Google Scholar
• Giustina A, Ambrosio MR, Beck Peccoz P, et al. Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J Endocrinol Invest. 2014;37(10):1017–1030.
   PubMed Web of Science ®Google Scholar
• Grottoli S, Maffei P, Bogazzi F, et al. ACROSTUDY: the Italian experience. Endocrine. Epub August 23, 2014.
   Google Scholar
• Buhk JH, Jung S, Psychogios MN, et al. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: A prospective multicenter study. J Clin Endocrinol Metab. 2010;95(2):552–558.
   PubMed Web of Science ®Google Scholar